Key result
Administration of allopurinol both before ischemia and before reperfusion significantly reduced mucosal malondialdehyde levels (24.0 vs 422.2 nmol/g protein, p<0.001) and attenuated histological damage compared to control.
Why the study?
Does the timing of allopurinol administration reduce ischemia-reperfusion injury in a rabbit model of small intestine ischemia?
Population
46 male New Zealand adult rabbits subjected to small intestine ischemia and reperfusion via superior…
Comparison
Allopurinol administered intravenously at… vs Control group receiving no allopurinol (Group A).
Design
Preclinical
Follow-up
50 minutes of reperfusion
Authors
Loading...
Hypothesis-generating for allopurinol timing in intestinal IRI models; leaves clinical translation open pending human trials.
Does the timing of allopurinol administration reduce ischemia-reperfusion injury in a rabbit model of small intestine ischemia?
Absolute Event Rate: 24% vs 422.2%
p-value: p=<0.001
In a rabbit model of small intestine ischemia-reperfusion, allopurinol provides maximum mucosal protection when administered as split doses both before ischemia and before reperfusion.
Gialamas et al. (2013) studied Ischemia reperfusion injury of the small intestine (n=46). Allopurinol vs. No allopurinol (Control) was evaluated on Mucosal malondialdehyde (MDA) concentration (nmol/g protein) (p=<0.001). Administration of allopurinol both before ischemia and before reperfusion significantly reduced mucosal malondialdehyde levels (24.0 vs 422.2 nmol/g protein, p<0.001) and attenuated histological damage compared to control.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: